Press release
August 12, 2026
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics, Inc. (IPSC)
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune